Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,902
archived clinical trials in
Irritable Bowel Syndrome (IBS)

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Hightop Medical Research Center
mi
from
Cincinnati, OH
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Hightop Medical Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
New Horizons Clinical Research
mi
from
Cincinnati, OH
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
New Horizons Clinical Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Remington Davis Inc.
mi
from
Columbus, OH
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Remington Davis Inc.
mi
from
Columbus, OH
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Dayton Gastroenterology, Inc.
mi
from
Dayton, OH
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Dayton Gastroenterology, Inc.
mi
from
Dayton, OH
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Hometown Urgent Care and Research
mi
from
Dayton, OH
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Hometown Urgent Care and Research
mi
from
Dayton, OH
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Great Lakes Gastroenterology Research
mi
from
Mentor, OH
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Great Lakes Gastroenterology Research
mi
from
Mentor, OH
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
IPS Research Company
mi
from
Oklahoma City, OK
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Partners in Clinical Research, LLC
mi
from
Cumberland, RI
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Partners in Clinical Research, LLC
mi
from
Cumberland, RI
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Mountain View Clinical Research
mi
from
Greer, SC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Mountain View Clinical Research
mi
from
Greer, SC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Meridian Clinical Research
mi
from
Dakota Dunes, SD
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Meridian Clinical Research
mi
from
Dakota Dunes, SD
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
ClinSearch, LLC
mi
from
Chattanooga, TN
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
ClinSearch, LLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
New Phase Research & Development
mi
from
Knoxville, TN
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
New Phase Research & Development
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
MW Clinical Research Center
mi
from
Beaumont, TX
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
MW Clinical Research Center
mi
from
Beaumont, TX
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Southwest Clinical Trials
mi
from
Houston, TX
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Southwest Clinical Trials
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Quality Research
mi
from
San Antonio, TX
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Quality Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Diagnostics Research Group
mi
from
San Antonio, TX
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Diagnostics Research Group
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Stone Oak, LLC dba Discovery Clinical Trials
mi
from
San Antonio, TX
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Stone Oak, LLC dba Discovery Clinical Trials
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Advanced Research Institute
mi
from
Ogden, UT
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Advanced Research Institute
mi
from
Ogden, UT
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
New River Valley Research Institute
mi
from
Christiansburg, VA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
New River Valley Research Institute
mi
from
Christiansburg, VA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Blue Ridge Medical Research
mi
from
Lynchburg, VA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Blue Ridge Medical Research
mi
from
Lynchburg, VA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Millennium Clinical Trials
mi
from
Thousand Oaks, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Millennium Clinical Trials
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Precision Clinical Research
mi
from
Sunrise, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Precision Clinical Research
mi
from
Sunrise, FL
Click here to add this to my saved trials
Multiple Dose Ethnobridging PK Study in Healthy Subjects
A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Adult Japanese Subjects
Status: Enrolling
Updated:  12/31/1969
Theravance Biopharma Investigational Site
mi
from
Cypress, CA
Multiple Dose Ethnobridging PK Study in Healthy Subjects
A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Adult Japanese Subjects
Status: Enrolling
Updated: 12/31/1969
Theravance Biopharma Investigational Site
mi
from
Cypress, CA
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Torrance Clinical Research
mi
from
Lomita, CA
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Torrance Clinical Research
mi
from
Lomita, CA
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Overland Park Family Health Partners
mi
from
Leawood, KA
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Overland Park Family Health Partners
mi
from
Leawood, KA
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
American Academy of Family Physicians-National Research Network
mi
from
Leawood, KA
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
American Academy of Family Physicians-National Research Network
mi
from
Leawood, KA
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Baton Rouge Family Practice
mi
from
Baton Rouge, LA
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Baton Rouge Family Practice
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Family Medicine of SE Missouri
mi
from
Sikeston, MO
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Family Medicine of SE Missouri
mi
from
Sikeston, MO
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Missouri Delta Physician Services
mi
from
Sikeston, MO
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Missouri Delta Physician Services
mi
from
Sikeston, MO
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Silver Sage Center for Family Medicine
mi
from
Reno, NV
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Silver Sage Center for Family Medicine
mi
from
Reno, NV
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Raj Kachoria
mi
from
Macedon, NY
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Raj Kachoria
mi
from
Macedon, NY
Click here to add this to my saved trials
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Southwest Family Medicine Associates
mi
from
Dallas, TX
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Southwest Family Medicine Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study To Evaluate the Bioavailability of BMS-986165 Tablet Formulation Relative To BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal And Increased Gastric pH on the Bioavailability of BMS-986165 Tablet Formulation in Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
PRA Health Sciences
mi
from
Salt Lake City, UT
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study To Evaluate the Bioavailability of BMS-986165 Tablet Formulation Relative To BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal And Increased Gastric pH on the Bioavailability of BMS-986165 Tablet Formulation in Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
PRA Health Sciences
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease
A Pilot Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease: The ALLAY Study
Status: Enrolling
Updated:  12/31/1969
CT Children's Medical Center
mi
from
Hartford, CT
Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease
A Pilot Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease: The ALLAY Study
Status: Enrolling
Updated: 12/31/1969
CT Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
Status: Enrolling
Updated:  10/7/2008
Children's Hospital - Boston
mi
from
Boston, MA
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
Status: Enrolling
Updated: 10/7/2008
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
Status: Enrolling
Updated:  10/7/2008
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
Status: Enrolling
Updated: 10/7/2008
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vitamin D Levels in Children With IBD
Optimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents With IBD.
Status: Enrolling
Updated:  1/27/2009
Children's Hospital Boston
mi
from
Boston, MA
Vitamin D Levels in Children With IBD
Optimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents With IBD.
Status: Enrolling
Updated: 1/27/2009
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
AcuGraph and Digestive Symptoms
Can AcuGraph Differentiate Between Participants With and Without Digestive Symptoms
Status: Enrolling
Updated:  2/17/2009
Logan University, College of Chiropractic
mi
from
Chesterfield, MO
AcuGraph and Digestive Symptoms
Can AcuGraph Differentiate Between Participants With and Without Digestive Symptoms
Status: Enrolling
Updated: 2/17/2009
Logan University, College of Chiropractic
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Nursing Management of Irritable Bowel Syndrome:Improving Outcomes
Nursing Management of Irritable Bowel Syndrome: Improving Outcomes
Status: Enrolling
Updated:  5/21/2009
Northgate Executive 1
mi
from
Seattle, WA
Nursing Management of Irritable Bowel Syndrome:Improving Outcomes
Nursing Management of Irritable Bowel Syndrome: Improving Outcomes
Status: Enrolling
Updated: 5/21/2009
Northgate Executive 1
mi
from
Seattle, WA
Click here to add this to my saved trials
Nursing Management of Irritable Bowel Syndrome:Improving Outcomes
Nursing Management of Irritable Bowel Syndrome: Improving Outcomes
Status: Enrolling
Updated:  5/21/2009
Univ of Washington
mi
from
Seattle, WA
Nursing Management of Irritable Bowel Syndrome:Improving Outcomes
Nursing Management of Irritable Bowel Syndrome: Improving Outcomes
Status: Enrolling
Updated: 5/21/2009
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)
Protocol- vs. Patient-Oriented TCM Practices: A RCT for IBS Symptom Management
Status: Enrolling
Updated:  7/22/2009
New York University, Division of Special Studies in Symptom Management
mi
from
New York, NY
Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)
Protocol- vs. Patient-Oriented TCM Practices: A RCT for IBS Symptom Management
Status: Enrolling
Updated: 7/22/2009
New York University, Division of Special Studies in Symptom Management
mi
from
New York, NY
Click here to add this to my saved trials
Iyengar Yoga for Young People With Irritable Bowel Syndrome
Iyengar Yoga for Young People With Irritable Bowel Syndrome
Status: Enrolling
Updated:  4/20/2010
UCLA Pediatric Pain Program
mi
from
Los Angeles, CA
Iyengar Yoga for Young People With Irritable Bowel Syndrome
Iyengar Yoga for Young People With Irritable Bowel Syndrome
Status: Enrolling
Updated: 4/20/2010
UCLA Pediatric Pain Program
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
A Pilot Study to Assess the Effects of Lubiprostone on Gastrointestinal and Colonic Motility and pH in Patients With the Irritable Bowel Syndrome and Constipation (IBS-C)
Status: Enrolling
Updated:  7/14/2010
University of Michigan Health System
mi
from
Ann Arbor, MI
Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
A Pilot Study to Assess the Effects of Lubiprostone on Gastrointestinal and Colonic Motility and pH in Patients With the Irritable Bowel Syndrome and Constipation (IBS-C)
Status: Enrolling
Updated: 7/14/2010
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Nursing Management of Irritable Bowel Syndrome (IBS) 2008
Nursing Management of IBS:Improving Outcomes
Status: Enrolling
Updated:  11/4/2010
University of Washington
mi
from
Seattle, WA
Nursing Management of Irritable Bowel Syndrome (IBS) 2008
Nursing Management of IBS:Improving Outcomes
Status: Enrolling
Updated: 11/4/2010
University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome.
Examining Patient Attributes To Determine Optimal Treatment Outcome in Irritable Bowel Syndrome.
Status: Enrolling
Updated:  2/15/2011
Michigan Gastroenterology Institute
mi
from
East Lansing, MI
Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome.
Examining Patient Attributes To Determine Optimal Treatment Outcome in Irritable Bowel Syndrome.
Status: Enrolling
Updated: 2/15/2011
Michigan Gastroenterology Institute
mi
from
East Lansing, MI
Click here to add this to my saved trials
Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography
Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography
Status: Enrolling
Updated:  4/25/2011
University of Virginia
mi
from
Charlottesville, VA
Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography
Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography
Status: Enrolling
Updated: 4/25/2011
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist
Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model
Status: Enrolling
Updated:  7/14/2011
The Vanderbilt Clinic
mi
from
Nashville, TN
Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist
Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model
Status: Enrolling
Updated: 7/14/2011
The Vanderbilt Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist
Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model
Status: Enrolling
Updated:  7/14/2011
Vanderbilt Childrens Hospital/ Pediatric Gastroenterology Clinic
mi
from
Nashville, TN
Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist
Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model
Status: Enrolling
Updated: 7/14/2011
Vanderbilt Childrens Hospital/ Pediatric Gastroenterology Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use
Decisional Influences and IBD Patients' Medication Use
Status: Enrolling
Updated:  7/14/2011
Inflammatory Bowel Disease Clinic c/o Divison of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, Vanderbilt University
mi
from
Nashville, TN
Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use
Decisional Influences and IBD Patients' Medication Use
Status: Enrolling
Updated: 7/14/2011
Inflammatory Bowel Disease Clinic c/o Divison of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD
Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease
Status: Enrolling
Updated:  9/21/2011
Children's Hospital of Michigan
mi
from
Detroit, MI
IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD
Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease
Status: Enrolling
Updated: 9/21/2011
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials